摘要
目的探讨西格列汀与阿卡波糖对初发2型糖尿病的治疗效果及胃肠道相关激素的影响。方法选取该院2012年5月—2013年12月收治的58例初发2型糖尿病患者为研究对象,随机将其分为两组,各29例,A组患者给予西格列汀治疗,B组患者给予阿卡波糖治疗,对两组患者血糖控制情况(空腹血糖、餐后2 h血糖及糖化血红蛋白)及胃肠道相关激素(胃饥饿素及胃泌素)变化进行比较。结果治疗后两组间血糖、血脂及体重质量指数变化比较,差异无统计学意义(P>0.05)。A组患者治疗后空腹、餐后2 h胃饥饿素及胃泌素较治疗前明显下降,差异有统计学意义(P<0.05),B组患者上述指标则无显著变化,差异无统计学意义(P>0.05)。结论西格列汀与阿卡波糖治疗初发2型糖尿病疗效均良好,但西格列汀可显著降低患者空腹及餐后胃饥饿素,更安全。
Objective To investigate the effects of sitagliptin and aearbose on newly diagnosed type 2 diabetes and gastrointestinal related hormones. Methods 58 cases with newly diagnosed type 2 diabetes admitted in our hospital from May 2012 to December 2013 were selected as the subjects and randomly divided into two groups with 29 cases in each. Patients in group A were treated by Sitagliptin, and patients in group B were treated by Acarbose. The changes of glycemic control （fasting blood glucose, 2-hour postprandial blood glucose and glycosylated hemoglobin） and gastrointestinal related hormones （ghrelin and gastrin） of the two groups were compared. Results After treatment, the changes in blood glucose, blood lipid and body mass index between the two groups had no statistically significant difference （P〉0.05）, The ghrelin and gastrin of group A at empty stomach and 2 hours after the meal decreased significantly compared with those before treatment （P〈0.05）, while group B had no significant changes in these indicators（P〉0.05）. Conclusion Both Sitagliptin and Acarbose have good effects on newly diagnosed type 2 diabetes, but Sitagliptin can significantly decrease the fasting and postprandial ghrelin with more safety.
出处
《糖尿病新世界》
2014年第11期3-4,6,共3页
Diabetes New World Magazine
关键词
西格列汀
阿卡波糖
初发2型糖尿病
胃肠道相关激素
疗效
Sitagliptin
Acarbose
Newly diagnosed type 2 diabetes
Gastrointestinal related hormones
Efficacy
